Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5% basliginda one cikan gelisme: Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.